Schizophrenia is a chronic mental illness, that affects people worldwide, and presents a significant challenge within the field of mental health. Because of its global rise in prevalence, the imperative to comprehend its underlying molecular mechanisms becomes increasingly vital. The complexity of this and other chronic mental illnesses presents significant diagnostic and treatment challenges, emphasizing the need for innovative approaches to address their intricate nature. Recent insights, as well as the focus of this thesis, aim to shed light on the occurrence of protein aggregation in the context of schizophrenia, offering new perspectives alongside genetics and environmental factors. This thesis focuses on the co-aggregation of TRIOBP-1 and NDE1, both of which play crucial roles in cellular processes and neurobiology and delves into their interaction, aiming to unravel their contributions to the disorder. Previous studies acknowledge NDE1's interactions with aggregating proteins like TRIOBP-1 and DISC1, underscoring its significance in this context. To investigate this co-aggregation further, we employed a range of methodologies. Plasmids were expressed in neuroblastoma cells, and their interactions were visualized using immunofluorescent microscopy. Western blot analysis confirmed the presence and expression levels of proteins. Additionally, we utilized an insoluble protein purification assay to validate the observed aggregates. Notably, our experiments revealed surprising findings, such as NDE1-inducing aggregation in mutant TRIOBP-1 and the co-aggregation of Flag-NDE1 and EGFP. These results shed light on the complex ways in which NDE1 can interact with other proteins. This research unveiled intricate protein interactions, emphasizing the ongoing need for a deeper understanding of this disorder. By unravelling the links between protein aggregation and schizophrenia, studies like this pave the way for more accurate diagnostics and innovative treatment approaches. These insights hold the promise of enhancing the quality of life for individuals with schizophrenia and driving further progress in this area.